Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for...
Transcript of Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for...
![Page 1: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/1.jpg)
Therapeutic Parasite Reduction or Removal of Harmful Materials
Yanyun Wu, MD, PhD
Chief Medical Officer
![Page 2: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/2.jpg)
Conflict of Interest
• None
![Page 3: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/3.jpg)
Puget Sound Blood Center is now Bloodworks Northwest After 70 years Puget Sound Blood Center is changing our name!
November 20, 2015, ASFA regional Meeting
![Page 4: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/4.jpg)
![Page 5: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/5.jpg)
Cases Case 1
A 53-year-old male resident of Connecticut was admitted to ER in July. He recently had a week-long camping trip.
He presented with high fevers (40 C), shaking chill, weakness, and fatigue. He had severe hemolytic anemia (Hct of 21%)/pancytopenia (platelet count of 33K), with signs of disseminated intravascular coagulation, acute renal failure, and respiratory failure. He was intubated and transferred to ICU overnight.
There was no history of splenectomy or immunodeficiency.
![Page 6: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/6.jpg)
Cases Case 2 • 60 year old woman with a prolonged hospital stay
(7 months) due to multiple medical and surgical issues.
• For the last week, patient has been spiking temp of 39 to 40 C.
• Significant DAT negative hemolytic anemia (Hct of 27%)
• She received transfusion of 4 units RBC 4 weeks ago. And she has a history of splenectomy
![Page 7: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/7.jpg)
Kyle Noskoviak, M.D., and Elizabeth Broome, M.D. N Engl J Med 2008; 358:e19April 24, 2008DOI: 10.1056/NEJMicm070903
![Page 8: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/8.jpg)
N Engl J Med 2012;366:2397-407.
![Page 9: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/9.jpg)
Human babesiosis summary
Causative pathogen: protozoal parasite in phylum Apicomplexa
Target tissue: red blood cells
Transmission:
Ixodid ticks (Ixodes scapularis)
Blood transfusion
Perinatal/transplacental
Diagnosis: epidemiology, symptoms, microscopy, PCR, antibody
Treatment: atovaquone/azithromycin or clindamycin/quinine, exchange transfusion
Courtesy of Dr. Peter Krause, Yale
![Page 10: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/10.jpg)
Babesia species causing human infection
US
• B. microti
• B. duncani
• B. divergens-like
Vannier and Krause, N. Engl. J. Med., 2012
Courtesy of Dr. Peter Krause, Yale
Europe • B. divergens • B. venatorum • B. microti
Asia • B. microti-like • K01
![Page 11: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/11.jpg)
Year
Nu
mb
er c
ases
Babesiosis in the US 1986-2011
0
100
200
300
400
500
600
700
800
900
1000
1100
86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11
Courtesy of Dr. Peter Krause, Yale
One of the most common infections of free-living animals worldwide and an emerging infection in humans
![Page 12: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/12.jpg)
Human babesiosis
• Require both a competent vertebrate and nonvertebrate host to maintain transmission cycles
• Transmitted by ixodid ticks to their vertebrate hosts
• Replicate in the vertebrate hosts’ red blood cells
![Page 13: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/13.jpg)
Vannier E and Krause PJ. New Engl J Med, 2012
Transmission of Babesia microti by the Ixodes scapularis Tick
Courtesy of Dr. Peter Krause, Yale
![Page 14: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/14.jpg)
Trophozoite
Merozoite
Pre-gametocyte
Gametes fuse
in the gut
Zygote enters
gut epithelium
Sporoblasts/Sporozoites
in salivary glands
Life cycle of Babesia microti
Courtesy of Dr. Peter Krause, Yale
![Page 15: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/15.jpg)
Life cycle of Babesia microti
![Page 16: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/16.jpg)
Babesiosis
![Page 17: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/17.jpg)
Babesiosis clinical manifestations
1. Asymptomatic infection 2. Viral-like illness Fever, chills, sweats, headache, fatigue 3. Severe illness and death (5-21%) >50, asplenic, HIV, malignancy, blood transfusion recipients • Persistent, relapsing illness HIV/AIDS, malignancy, asplenic, immunosuppressive drugs • The incubation period is usually 1–3 weeks
Courtesy of Dr. Peter Krause, Yale
![Page 18: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/18.jpg)
Babesiosis: persistent parasitemia
(DNA)
Krause, Spielman, Telford, et al., New Engl J Med, 1998
Courtesy of Dr. Peter Krause, Yale
![Page 19: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/19.jpg)
Transfusion transmitted babesiosis
• Symptoms delayed as long as 1 week to 6 months after transfusion
• Symptoms similar to those of tick-transmitted disease but often more severe because blood recipients are often immunocompromised
• Mortality rate ranges from about 10% to 21%
Courtesy of Dr. Peter Krause, Yale
![Page 20: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/20.jpg)
Babesiosis in highly immunocompromised patients
Clinical characteristic Cases
(n=14)
Controls
(n=46)
P value
Median number of antibiotic courses
(range)
4 (2-10) 1 <0.001
Median number hospital admissions
(range)
1.5 (0-4) 1 (0-1) <0.001
Median weeks of therapy (range) 13 (4-
102)
1 (0.5-1.5) <0.001
Number with complications (percent) 8 (57) 2 (4) <0.001
Number with fatal infection (percent) 3 (21) 0 <0.02
Krause, Gewurz, Hill, et al. Clin Inf Dis, 2008
Courtesy of Dr. Peter Krause, Yale
![Page 21: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/21.jpg)
Babesiosis in highly immunocompromised patients • People suffering from broad-based immunosuppression are at risk of persistent relapsing Babesia microti infection
• Adaptive immunity (B and T cell) are important for resolution of infection
• These patients generally require anti-babesial therapy for at least 6 weeks, including 2 weeks after babesia are no longer detected on blood smear
Courtesy of Dr. Peter Krause, Yale
![Page 22: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/22.jpg)
General approach to diagnosis
Epidemiology
Medical history
Physical examination
Laboratory testing
Courtesy of Dr. Peter Krause, Yale
![Page 23: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/23.jpg)
Specific laboratory diagnosis
Microbial detection
Blood smear
Polymerase chain reaction
Small rodent inoculation
Antibody detection
IFA
Immunoblot
ELISA
Courtesy of Dr. Peter Krause, Yale
![Page 24: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/24.jpg)
Diagnostic algorithm for babesiosis
Cunha et al, Clinical Infectious Diseases® 2015;60(5):827–9
![Page 25: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/25.jpg)
Diagnosis
Cunha et al, Clinical Infectious Diseases® 2015;60(5):827–9
![Page 26: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/26.jpg)
Treatment of babesiosis caused by Babesia microti
Mild illness Atovaquone (PO) + azithromycin (PO) Administration for 7-10 days
Severe illness Clindamycin (IV or PO) + quinine (PO) Administration for 7-10 days
Persistent or relapsing illness Atovaquone (PO) + azithromycin (PO) OR Clindamycin (IV or PO) + quinine (PO) Administration for at least 6 wks, including 2 wks after parasites are no longer detected on blood smear
Courtesy of Dr. Peter Krause, Yale
![Page 27: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/27.jpg)
Babesiosis
![Page 28: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/28.jpg)
Babesiosis
• What are we removing?
• What are we adding back?
• Have we changed patient outcome?
• Give me the proof!
• Show me the data!
![Page 29: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/29.jpg)
Babesiosis
Readings: 1. Dorman et al, TRANSFUSION Volume 40, March 2000 2. Spaete et al, Journal of Clinical Apheresis 24:97–105 (2009)
![Page 30: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/30.jpg)
Babesiosis
Dorman et al, TRANSFUSION Volume 40, March 2000
![Page 31: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/31.jpg)
Dorman et al, TRANSFUSION Volume 40, March 2000
![Page 32: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/32.jpg)
Dorman et al, TRANSFUSION Volume 40, March 2000
![Page 33: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/33.jpg)
Dorman et al, TRANSFUSION Volume 40, March 2000
![Page 34: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/34.jpg)
Dorman et al, TRANSFUSION Volume 40, March 2000
![Page 35: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/35.jpg)
Summary
• 15 males (63%)
• The mean age: 56 years (SD 16; range, 25–77)
• The mean pretransfusion hemoglobin: 8.1 g/dl (SD 2.5; range, 4.7–13.7).
• The mean preRCE or preWBE level of parasitemia was 18% (SD 14; range, 1.6–60)
• The mean postExchange level of parasitemia was 3.6% (SD 3.8; range, 0.1–13.8) with a median of 2%
• Fifteen (63%) of the 24 patients were asplenic
• Two of four who died were asplenic, and a third was reported to have necrotic splenic lesions on postmortem exam
![Page 36: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/36.jpg)
Babesiosis
Spaete J et al, J Clin Apher. 2009;24(3):97-105.
![Page 37: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/37.jpg)
Babesiosis
![Page 38: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/38.jpg)
Babesiosis
Harmful Materials:
• Parasite: from RBC only?
• Cytokine?
• Free Heme
• Others?
![Page 39: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/39.jpg)
ASFA guideline: Rationale for therapeutic apheresis
1. First, it helps to lower the level of parasitemia by physically removing the infected RBCs from the blood stream and replacing them with noninfected RBCs. Because babesia organisms do not have an exo-erthrocytic phase, removal of RBC-associated parasites might be very effective.
2. Second, by removal of rigid infected cells, RBC exchange could decrease obstruction in the microcirculation and tissue hypoxia caused by adherence of RBCs to vascular endothelium.
3. Finally, the hemolytic process produces vasoactive compounds, including a variety of cytokines (including INF-g, TNF-a, IL-1, IL-6), nitric oxide and thromboplastin substances, which can promote renal failure and DIC. RBC exchange may help to remove the proinflammatory cytokines.
![Page 40: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/40.jpg)
Babesiosis
Shaio MF et al. Am J Trop Med Hyg. (1998)
![Page 41: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/41.jpg)
Babesiosis
Shaio MF et al. Am J Trop Med Hyg. (1998)
![Page 42: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/42.jpg)
Krause PJ, et al. Trends in Parasitology, 2007;23:605-610.
Courtesy of Dr. Peter Krause, Yale
![Page 43: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/43.jpg)
Pathogenesis
Excessive erythrocyte cytoadherence: Additionally, erythrocytes infected with some babesia species
undergo membrane changes that cause these erythrocytes to adhere to the vascular endothelium Excessive pro-inflammatory cytokine production During a babesia infection, inflammatory cytokines including tumor
necrosis factor a (TNF-a) and interleukin 6, and adhesion molecules such as Eselectin, intracellular adhesion molecule 1 and vascular-cell adhesion molecule 1 are upregulated
While moderate synthesis of these factors may be protective,
excessive upregulation may result in severe babesiosis
Krause PJ, Daily J, Telford SR, et al. Trends Parasitol, 2007
Sloan et al, Journal of Clinical Apheresis 00:00–00 (2014)
![Page 44: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/44.jpg)
• Cytoadherence most thoroughly studied in B. bovis infection
• Cattle infected by B. bovis die from encephalopathy as erythrocytes obstruct brain blood vessels.
• B. bovis encephalopathy similar to human P. falciparum cerebral malaria
• Cytoadherence is beneficial for the parasite as it delays or prevents filtering/removal of infected RBCs by the spleen.
Erythrocyte cytoadherence
Courtesy of Dr. Peter Krause, Yale
![Page 45: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/45.jpg)
Pro-inflammatory cytokines
• Severe disease occurs without erythrocyte cytoadherence for B. microti, suggesting other pathogenic mechanisms.
• Pro-inflammatory cytokines such as TNF-α and IFN-γ protect the host against B. microti infection but if produced in excess may cause severe symptoms and complications.
Courtesy of Dr. Peter Krause, Yale
![Page 46: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/46.jpg)
Babesiosis
• When do you start or stop?
• How to exchange?
• Patient consent?
• Others?
![Page 47: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically](https://reader033.fdocuments.net/reader033/viewer/2022051909/5ffde1a612ad7e6b4a3ede92/html5/thumbnails/47.jpg)
Babesiosis
Ziggy Vote
1. Agree with ASFA Category? 2. More Study?
a. RCT? b. CT? c. Registry?
3. What kind of exchange? a. RBC b. RBC+ Plasma? c. Whole Blood?